Equivalent gene expression profiles between glatopa™ and copaxone®

Josephine S. D'Alessandro, Jay Duffner, Joel Pradines, Ishan Capila, Kevin Garofalo, Ganesh Kaundinya, Benjamin M. Greenberg, Daniel Kantor, Tanmoy C. Ganguly

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Glatopa™is a generic glatiramer acetate recently approved for the treatment of patients with relapsing forms of multiple sclerosis. Gene expression profiling was performed as a means to evaluate equivalence of Glatopa and Copaxone1. Microarray analysis containing 39,429 unique probes across the entire genome was performed in murine glatiramer acetate-responsive Th2-polarized T cells, a test system highly relevant to the biology of glatiramer acetate. A closely related but nonequivalent glatiramoid molecule was used as a control to establish assay sensitivity. Multiple probe-level (Student's t-test) and samplelevel (principal component analysis, multidimensional scaling, and hierarchical clustering) statistical analyses were utilized to look for differences in gene expression induced by the test articles. The analyses were conducted across all genes measured, as well as across a subset of genes that were shown to be modulated by Copaxone. The following observations were made across multiple statistical analyses: the expression of numerous genes was significantly changed by treatment with Copaxone when compared against media-only control; gene expression profiles induced by Copaxone and Glatopa were not significantly different; and gene expression profiles induced by Copaxone and the nonequivalent glatiramoid were significantly different, underscoring the sensitivity of the test system and the multiple analysis methods. Comparative analysis was also performed on sets of transcripts relevant to T-cell biology and antigen presentation, among others that are known to be modulated by glatiramer acetate. No statistically significant differences were observed between Copaxone and Glatopa in the expression levels (magnitude and direction) of these glatiramer acetate-regulated genes. In conclusion, multiple methods consistently supported equivalent gene expression profiles between Copaxone and Glatopa.

Original languageEnglish (US)
Article numbere0140299
JournalPLoS One
Volume10
Issue number10
DOIs
StatePublished - Oct 16 2015

Fingerprint

Transcriptome
Gene expression
gene expression
acetates
Genes
T-lymphocytes
T-cells
antigen presentation
genes
testing
sclerosis
cell biology
Glatiramer Acetate
principal component analysis
Cytology
T-Lymphocytes
Gene Expression
Biological Sciences
Viral Tumor Antigens
Antigen Presentation

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

D'Alessandro, J. S., Duffner, J., Pradines, J., Capila, I., Garofalo, K., Kaundinya, G., ... Ganguly, T. C. (2015). Equivalent gene expression profiles between glatopa™ and copaxone®. PLoS One, 10(10), [e0140299]. https://doi.org/10.1371/journal.pone.0140299

Equivalent gene expression profiles between glatopa™ and copaxone®. / D'Alessandro, Josephine S.; Duffner, Jay; Pradines, Joel; Capila, Ishan; Garofalo, Kevin; Kaundinya, Ganesh; Greenberg, Benjamin M.; Kantor, Daniel; Ganguly, Tanmoy C.

In: PLoS One, Vol. 10, No. 10, e0140299, 16.10.2015.

Research output: Contribution to journalArticle

D'Alessandro, JS, Duffner, J, Pradines, J, Capila, I, Garofalo, K, Kaundinya, G, Greenberg, BM, Kantor, D & Ganguly, TC 2015, 'Equivalent gene expression profiles between glatopa™ and copaxone®', PLoS One, vol. 10, no. 10, e0140299. https://doi.org/10.1371/journal.pone.0140299
D'Alessandro JS, Duffner J, Pradines J, Capila I, Garofalo K, Kaundinya G et al. Equivalent gene expression profiles between glatopa™ and copaxone®. PLoS One. 2015 Oct 16;10(10). e0140299. https://doi.org/10.1371/journal.pone.0140299
D'Alessandro, Josephine S. ; Duffner, Jay ; Pradines, Joel ; Capila, Ishan ; Garofalo, Kevin ; Kaundinya, Ganesh ; Greenberg, Benjamin M. ; Kantor, Daniel ; Ganguly, Tanmoy C. / Equivalent gene expression profiles between glatopa™ and copaxone®. In: PLoS One. 2015 ; Vol. 10, No. 10.
@article{5b3301e9feba4a2dba068b3d8878eb27,
title = "Equivalent gene expression profiles between glatopa™ and copaxone{\circledR}",
abstract = "Glatopa™is a generic glatiramer acetate recently approved for the treatment of patients with relapsing forms of multiple sclerosis. Gene expression profiling was performed as a means to evaluate equivalence of Glatopa and Copaxone1. Microarray analysis containing 39,429 unique probes across the entire genome was performed in murine glatiramer acetate-responsive Th2-polarized T cells, a test system highly relevant to the biology of glatiramer acetate. A closely related but nonequivalent glatiramoid molecule was used as a control to establish assay sensitivity. Multiple probe-level (Student's t-test) and samplelevel (principal component analysis, multidimensional scaling, and hierarchical clustering) statistical analyses were utilized to look for differences in gene expression induced by the test articles. The analyses were conducted across all genes measured, as well as across a subset of genes that were shown to be modulated by Copaxone. The following observations were made across multiple statistical analyses: the expression of numerous genes was significantly changed by treatment with Copaxone when compared against media-only control; gene expression profiles induced by Copaxone and Glatopa were not significantly different; and gene expression profiles induced by Copaxone and the nonequivalent glatiramoid were significantly different, underscoring the sensitivity of the test system and the multiple analysis methods. Comparative analysis was also performed on sets of transcripts relevant to T-cell biology and antigen presentation, among others that are known to be modulated by glatiramer acetate. No statistically significant differences were observed between Copaxone and Glatopa in the expression levels (magnitude and direction) of these glatiramer acetate-regulated genes. In conclusion, multiple methods consistently supported equivalent gene expression profiles between Copaxone and Glatopa.",
author = "D'Alessandro, {Josephine S.} and Jay Duffner and Joel Pradines and Ishan Capila and Kevin Garofalo and Ganesh Kaundinya and Greenberg, {Benjamin M.} and Daniel Kantor and Ganguly, {Tanmoy C.}",
year = "2015",
month = "10",
day = "16",
doi = "10.1371/journal.pone.0140299",
language = "English (US)",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Equivalent gene expression profiles between glatopa™ and copaxone®

AU - D'Alessandro, Josephine S.

AU - Duffner, Jay

AU - Pradines, Joel

AU - Capila, Ishan

AU - Garofalo, Kevin

AU - Kaundinya, Ganesh

AU - Greenberg, Benjamin M.

AU - Kantor, Daniel

AU - Ganguly, Tanmoy C.

PY - 2015/10/16

Y1 - 2015/10/16

N2 - Glatopa™is a generic glatiramer acetate recently approved for the treatment of patients with relapsing forms of multiple sclerosis. Gene expression profiling was performed as a means to evaluate equivalence of Glatopa and Copaxone1. Microarray analysis containing 39,429 unique probes across the entire genome was performed in murine glatiramer acetate-responsive Th2-polarized T cells, a test system highly relevant to the biology of glatiramer acetate. A closely related but nonequivalent glatiramoid molecule was used as a control to establish assay sensitivity. Multiple probe-level (Student's t-test) and samplelevel (principal component analysis, multidimensional scaling, and hierarchical clustering) statistical analyses were utilized to look for differences in gene expression induced by the test articles. The analyses were conducted across all genes measured, as well as across a subset of genes that were shown to be modulated by Copaxone. The following observations were made across multiple statistical analyses: the expression of numerous genes was significantly changed by treatment with Copaxone when compared against media-only control; gene expression profiles induced by Copaxone and Glatopa were not significantly different; and gene expression profiles induced by Copaxone and the nonequivalent glatiramoid were significantly different, underscoring the sensitivity of the test system and the multiple analysis methods. Comparative analysis was also performed on sets of transcripts relevant to T-cell biology and antigen presentation, among others that are known to be modulated by glatiramer acetate. No statistically significant differences were observed between Copaxone and Glatopa in the expression levels (magnitude and direction) of these glatiramer acetate-regulated genes. In conclusion, multiple methods consistently supported equivalent gene expression profiles between Copaxone and Glatopa.

AB - Glatopa™is a generic glatiramer acetate recently approved for the treatment of patients with relapsing forms of multiple sclerosis. Gene expression profiling was performed as a means to evaluate equivalence of Glatopa and Copaxone1. Microarray analysis containing 39,429 unique probes across the entire genome was performed in murine glatiramer acetate-responsive Th2-polarized T cells, a test system highly relevant to the biology of glatiramer acetate. A closely related but nonequivalent glatiramoid molecule was used as a control to establish assay sensitivity. Multiple probe-level (Student's t-test) and samplelevel (principal component analysis, multidimensional scaling, and hierarchical clustering) statistical analyses were utilized to look for differences in gene expression induced by the test articles. The analyses were conducted across all genes measured, as well as across a subset of genes that were shown to be modulated by Copaxone. The following observations were made across multiple statistical analyses: the expression of numerous genes was significantly changed by treatment with Copaxone when compared against media-only control; gene expression profiles induced by Copaxone and Glatopa were not significantly different; and gene expression profiles induced by Copaxone and the nonequivalent glatiramoid were significantly different, underscoring the sensitivity of the test system and the multiple analysis methods. Comparative analysis was also performed on sets of transcripts relevant to T-cell biology and antigen presentation, among others that are known to be modulated by glatiramer acetate. No statistically significant differences were observed between Copaxone and Glatopa in the expression levels (magnitude and direction) of these glatiramer acetate-regulated genes. In conclusion, multiple methods consistently supported equivalent gene expression profiles between Copaxone and Glatopa.

UR - http://www.scopus.com/inward/record.url?scp=84949024023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949024023&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0140299

DO - 10.1371/journal.pone.0140299

M3 - Article

C2 - 26473741

AN - SCOPUS:84949024023

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e0140299

ER -